A new drug could let those with severe food allergies breathe a sigh of relief. Xolair, or omalizumab, was granted priority review by the Food and Drug Administration on Tuesday for its use in ...

The injection is the first of its kind. Getty The U.S. Food and Drug Administration (FDA) has approved a medication for use in treating severe food allergies, and the agency says that this injection ...

A new study finds that the asthma medication Xolair may substantially reduce severe allergic reactions in people who have multiple food allergies and are accidentally exposed to those foods. Data ...

ATLANTA - If you have to be vigilant about what you eat, and keep an EpiPen close, Dr. Tom Chacko of Chacko Allergy, Asthma and Sinus Center, says the newly FDA-authorized allergy medication, Xolair, ...

CHICAGO (WLS) -- After the FDA approved a medication called Xolair to help lessen the severity of an accidental allergic reaction in people who are allergic to multiple foods, sufferers say they're ...

A medication used to treat asthma can now be used to help people with food allergies avoid severe reactions, the U.S. Food and Drug Administration said Friday. Xolair, the brand name for the drug ...

A new treatment appears to reduce food allergies in children and teens, according to interim clinical trial results. A lab-made monoclonal antibody called omalizumab (Xolair) significantly increased ...

Xolair is a prescription biologic medicine that is given as an injection under the skin (subcutaneous). It is the only FDA-approved antibody designed to target and block IgE — an underlying driver of ...

SAN DIEGO -- Omalizumab (Xolair) injections outperformed oral immunotherapy (OIT) in increasing tolerance among children with multi-food allergy, largely because many patients couldn't tolerate OIT, ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has approved the ...

Approval is based on data from the NIH-sponsored Phase III OUtMATCH study, which showed a significantly higher proportion of food allergy patients as young as 1 year treated with Xolair could tolerate ...